* alt/ast \> 5 times the upper limit of normal. * patients with severe hepatic impairment (defined as liver cirrhosis child stage b or c) * stage 4 chronic kidney disease or requiring dialysis (i.e. egfr \< 30 ml/min) * advanced cardiac (eg, severe heart failure \[nyha iii-iv\]) or pulmonary diseases which, in the investigator's judgment, would not make participation appropriate. * pregnancy or breast feeding. * anticipated transfer to another hospital which is not a study site within 72 hours. * known allergy or hypersensitivity to cvc or its components. * use of medications that are contraindicated with cvc and that could not be replaced or stopped during the trial period * administration of specified drugs which interfere with the metabolism of cvc. * patients immediately or imminently requiring mechanical ventilation. * patients unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. * subjects who are legally detained in an official institution. * subjects that are unsuitable to understand or to comply with the study requirements in the opinion of the investigator. * subjects who may be dependent on the sponsor, the investigator or the trial sites.

* alt/ast \> 5 times the upper limit of normal. * patients with severe hepatic impairment (defined as liver cirrhosis child stage b or c) * stage 4 chronic kidney disease or requiring dialysis (i.e. egfr \< 30 ml/min) * advanced cardiac (eg, severe heart failure \[nyha iii-iv\]) or pulmonary diseases which, in the investigator's judgment, would not make participation appropriate. * pregnancy or breast feeding. * anticipated transfer to another hospital which is not a study site within 72 hours. * known allergy or hypersensitivity to cvc or its components. * use of medications that are contraindicated with cvc and that could not be replaced or stopped during the trial period * administration of specified drugs which interfere with the metabolism of cvc. * patients immediately or imminently requiring mechanical ventilation. * patients unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. * subjects who are legally detained in an official institution. * subjects that are unsuitable to understand or to comply with the study requirements in the opinion of the investigator. * subjects who may be dependent on the sponsor, the investigator or the trial sites.

- alt/ast > 5 times the upper limit of normal. - patients with severe hepatic impairment (defined as liver cirrhosis child stage b or c) - stage 4 chronic kidney disease or requiring dialysis (i.e. egfr < 30 ml/min) - advanced cardiac (eg, severe heart failure [nyha iii-iv]) or pulmonary diseases which, in the investigator's judgment, would not make participation appropriate. - pregnancy or breast feeding. - anticipated transfer to another hospital which is not a study site within 72 hours. - known allergy or hypersensitivity to cvc or its components. - use of medications that are contraindicated with cvc and that could not be replaced or stopped during the trial period - administration of specified drugs which interfere with the metabolism of cvc. - patients immediately or imminently requiring mechanical ventilation. - patients unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. - subjects who are legally detained in an official institution. - subjects that are unsuitable to understand or to comply with the study requirements in the opinion of the investigator. - subjects who may be dependent on the sponsor, the investigator or the trial sites.

- alt/ast > 5 times the upper limit of normal. - patients with severe hepatic impairment (defined as liver cirrhosis child stage b or c) - stage 4 chronic kidney disease or requiring dialysis (i.e. egfr < 30 ml/min) - advanced cardiac (eg, severe heart failure [nyha iii-iv]) or pulmonary diseases which, in the investigator's judgment, would not make participation appropriate. - pregnancy or breast feeding. - anticipated transfer to another hospital which is not a study site within 72 hours. - known allergy or hypersensitivity to cvc or its components. - use of medications that are contraindicated with cvc and that could not be replaced or stopped during the trial period - administration of specified drugs which interfere with the metabolism of cvc. - patients immediately or imminently requiring mechanical ventilation. - patients unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. - subjects who are legally detained in an official institution. - subjects that are unsuitable to understand or to comply with the study requirements in the opinion of the investigator. - subjects who may be dependent on the sponsor, the investigator or the trial sites.